Lexicon is betting its future on new heart and pain medicines, but tougher regulators and longer trials could slow progress and keep the business under strain. With more of its funding tied to big partners and a lighter sales approach for its current drug, there’s a real question of whether the pipeline can deliver before cash runs tight.Read more
Lexicon is betting that two new pills in development can open up big new areas like nerve pain and obesity, while a key study could broaden the uses of one of its existing drugs. At the same time, the plan leans on partners and heavy trial spending, so delays or setbacks could quickly pressure the business.Read more
Catalysts About Lexicon Pharmaceuticals Lexicon Pharmaceuticals is a biopharmaceutical company focused on developing and partnering innovative medicines for cardiometabolic diseases and neuropathic pain. What are the underlying business or industry changes driving this perspective?Read more
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors. In addition, the company develops LX9851, an orally-delivered small molecule drug candidate for the treatment of obesity and associated cardiometabolic disorders, and pilavapadin (LX9211), an orally-delivered small molecule drug candidate for the treatment of neuropathic pain. It has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
